Neurodegenerative Disease Treatment Drug PBT2 Breaks Intrinsic Polymyxin Resistance in Gram-Positive Bacteria

• Main Authors: David M. P. De Oliveira (Author), Bernhard Keller (Author), Andrew J. Hayes (Author), Cheryl-Lynn Y. Ong (Author), Nichaela Harbison-Price (Author), Ibrahim M. El-Deeb (Author), Gen Li (Author), Nadia Keller (Author), Lisa Bohlmann (Author), Stephan Brouwer (Author), Andrew G. Turner (Author), Amanda J. Cork (Author), Thomas R. Jones (Author), David L. Paterson (Author), Alastair G. McEwan (Author), Mark R. Davies (Author), Christopher A. McDevitt (Author), Mark von Itzstein (Author), Mark J. Walker (Author)
• Format: Book
• Published: MDPI AG, 2022-03-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Gram-positive bacteria do not produce lipopolysaccharide as a cell wall component. As such, the polymyxin class of antibiotics, which exert bactericidal activity against Gram-negative pathogens, are ineffective against Gram-positive bacteria. The safe-for-human-use hydroxyquinoline analog ionophore...